Avitia and Genoscience Unlock Province-Wide Access to Targeted Liquid Biopsy Testing

Partnership brings Avitia’s cost-effective Follow It© panel to over 45 partner and seven Genoscience-owned clinics, advancing precision cancer diagnostics in Quebec

Montreal, Quebec – September 23, 2025 – Avitia, a leader in AI-powered liquid biopsy diagnostics, today announced a new partnership with Genoscience (dba Genolife) to expand access to its Follow It© panel across Quebec. Through this collaboration,  patients will now be able to access cutting-edge, non-invasive molecular cancer testing at over 45  Genosciences-affiliated clinics and seven laboratories — significantly reducing wait times while improving treatment decision-making for cancer care.  

Avitia’s Follow It© panel uses next-generation sequencing (NGS) to deliver fast, affordable, and targeted molecular insights from a single, liquid biopsy blood draw. This non-invasive test detects cancer mutations by analyzing biomarkers, such as circulating tumor DNA (ctDNA) or RNA. As a result of Avitia’s partnership with Genoscience, oncologists and physicians across Quebec can offer advanced testing without sending samples to distant labs. OncoHelix will work in collaboration with this partnership, leveraging their clinically accredited laboratory to support testing and analysis. The initiative eliminates cross-border delays, reducing time-to-treatment and improving access in both urban and remote regions.

“Avitia’s partnership with Genoscience is breaking barriers in access to precision diagnostics — bringing fast, affordable testing to communities across Quebec and continuing our pledge to deliver localized, cost-effective cancer care,” said Avitia CEO James Lumsdaine. “Avitia’s uniquely targeted Follow It© panel, paired with our AI-powered bioinformatics platform, enables us to generate precise treatment pathways from a single blood draw at Genoscience — getting patients on the right therapy or clinical trial faster.”

The partnership also strengthens regional bioinformatics and clinical integration by allowing patients to be tested locally and data to be analyzed with reference to local populations. The platform identifies relevant mutations and matches them with optimal therapies or clinical trials that are available to the specific patient. Avitia’s technology also delivers actionable reports directly to treating physicians, enabling more tailored care based on genetics, lifestyle, and local population data.

“Genosciences is proud to join forces with Avitia and in our quest to expand access to the most advanced liquid biopsy cancer testing in Quebec,” said Martin Landry, President of Genosciences. “Together, we’re not only making liquid biopsy more accessible across Quebec — we’re actively working to reduce barriers to reimbursement and ensure that cost never stands between a patient and the care they deserve.”

‍

About Avitia

Avitia delivers advanced NGS-molecular testing solutions directly to laboratories via the company’s AI/ML platform. The company’s modular precision medicine technology equips clinical laboratories with cutting-edge NGS capabilities and network-wide insights. With Avitia’s automated platform, any lab can conduct liquid biopsy and tissue molecular testing on-site — reducing testing time and cost while improving patient outcomes. With Avitia’s solutions available across Canada, the Middle East, and Southeast Asia — together with partners including Genoscience, OncoHelix, and Vancouver General Hospital (VGH) — local oncologists are empowered to best serve their communities. For rapid, cost-effective, and high-fidelity molecular diagnostic solutions, contact Avitia today: www.avitia.bio  

About Genoscience

GENOSCIENCE DIAGNOSTIC is a group of private clinics founded in 2016 in Quebec City whose mission is to offer genetic screening and support services as part of a preventive and personalized medical approach. www.genoscience.com  

‍

Media Contact
Peter Weltman
peter@mow.media
+1 (424) 460-0537